Experimental Evaluation of the Combined Effects of a GLP-1 Agonist and a SGLT2 Inhibitor in a Metabolic Syndrome Model

Abstract

This study experimentally evaluated the effects of separate and combined administration of a GLP-1 agonist (liraglutide) and an SGLT2 inhibitor (dapagliflozin) on metabolic parameters in a metabolic syndrome (MetS) model. MetS was induced using a 12-week high-fat/high-fructose diet, followed by a 4-week pharmacological intervention. The results showed that the GLP-1 RA + SGLT2 inhibitor combination produced greater reductions in body weight, improved glucose tolerance, lowered HOMA-IR, optimized lipid profile, reversed hepatic steatosis, and significantly reduced oxidative stress markers. The combined therapy demonstrated a strong synergistic effect compared with monotherapy.